Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research ...
H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from $20, following the ...
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Shares of Checkpoint Therapeutics surged in premarktet trading Monday after the immunotherapy and targeted oncology company agreed to be acquired by Indian pharmaceutical giant Sun Pharmaceutical ...
GlobalData on MSN2d
Sun Pharma agrees to acquire Checkpoint TherapeuticsSun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and ...
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities ...
On March 9, 2023, Checkpoint announced the deal with Sun Pharma, under which shareholders will receive $4.10 per share in cash (or a total of $355 million). if cosibelimab receives EU approval within ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback